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Abstract
Hyperuricemia is associated with the metabolic syndrome, gout, renal and cardiovascular disease
(CVD). American Indians have high rates of CVD and 25 % of individuals in the Strong Heart Family
Study (SHFS) have high serum uric acid levels. The aim of this study was to investigate the genetic
determinants of serum uric acid variation in American Indian participants of the SHFS. A variance
component decomposition approach (implemented in SOLAR) was used to conduct univariate
genetic analyses in each of three study centers and the combined sample. Serum uric acid was adjusted
for age, sex, age*sex, BMI, estimated glomerular filtration rate, alcohol intake, diabetic status and
medications. Overall mean ± SD serum uric acid for all individuals was 5.14 ± 1.5 mg/dl. Serum uric
acid was found to be significantly heritable (0.46 ± 0.03 in all centers, and 0.39 ± 0.07, 0.51 ± 0.05,
0.44 ± 0.06 in Arizona, Dakotas and Oklahoma, respectively). Multipoint linkage analysis showed
significant evidence of linkage for serum uric acid on chromosome 11 in the Dakotas center
(logarithm of odds score (LOD) = 3.02) and in the combined sample (LOD = 3.56) and on
chromosome 1 (LOD = 3.51) in the combined sample. A strong positional candidate gene in the
chromosome 11 region is solute carrier family22, member 12 (SLC22A12) that encodes a major uric
acid transporter URAT1. These results show a significant genetic influence and a possible role for
one or more genes on chromosomes 1 and 11 on the variation in serum uric acid in American Indian
populations.
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Increased serum uric acid or hyperuricemia is associated with gout, renal and cardiovascular
disease (CVD) and the metabolic syndrome (Nakagawa et al. 2006). Although serum uric acid
has been more closely associated with gout, its association with CVD has recently been
recognized (Alderman 2002; Johnson et al. 2005; Chen et al., 2009). Serum uric acid has been
independently associated with insulin resistance, hypertension, dyslipidemia and obesity
(Hayden and Tyagi 2004; Forman et al., 2009), all disorders that are elements of the metabolic
syndrome (Conen et al. 2004; Onat et al. 2006; Nan et al. 2008). Even in individuals with
serum uric acid levels in the normal range, it was found that increasing serum uric acid was
associated with an increased risk of metabolic syndrome (Yoo et al. 2005; Hikita et al. 2007).
Higher serum uric acid levels have also been linked to increased risk of developing type 2
diabetes (Dehghan et al. 2008a). Endothelial dysfunction, another common finding in renal
and CVD patients, may be induced by increased serum uric acid (Khosla et al. 2005). The
possible mechanisms by which serum uric acid may have pathogenic role in CVD are i)
promoting lipid peroxidation by oxygenation of low density lipoprotein cholesterol, ii)
increasing production of free oxygen radicals and thus increasing the risk for atherosclerosis,
iii) increasing platelet aggregation, and iv) inducing renal hypertension by intrarenal crystal
deposition (Alderman 2002). However, it is not clear whether serum uric acid is an independent
risk factor of CVD or is merely associated with other CVD risk factors or metabolic syndrome
components. Irrespective of its importance as an independent risk factor, elevated serum uric
acid is a matter of concern in individuals at risk for CVD (Hayden and Tyagi 2004).
Serum uric acid concentrations are highly variable in humans. Age, ethnicity, sex, high purine
nutrient intake, alcohol consumption, defects in purine metabolism and genetic factors
influence serum uric acid levels (Johnson et al. 2003). In addition, medications including
losartan, allopurinol, diuretics and other hypertension medications impact uric acid metabolism
(Sica and Schoolwerth 2002). Serum urate levels have been found to be significantly heritable
in family-based studies (Rao et al. 1982; Rice et al. 1990; Tang et al. 2003; Yang et al.
2005; Nath et al. 2007; Voruganti et al. 2009). A few genome-wide studies of serum uric acid
have been conducted in Caucasian, African American and Mexican American population with
relatively little replication of chromosomal locations (Tang et al. 2003; Yang et al. 2005; Nath
et al. 2007; Voruganti et al. 2009).
The Strong Heart Family Study (SHFS) is an extension of an ongoing, longitudinal study of
CVD in American Indians, the Strong Heart Study (SHS). American Indians have high rates
of CVD and CVD-related mortality (Howard et al. 1999; North et al. 2003). Serum uric acid
values can vary substantially based on ethnicity and geography (Alderman 2002). Serum uric
acid levels > 7 mg/dl in men and 6mg/dl in women are considered high (Rathmann et al.,
1998; Krishnan et al., 2007). However, serum uric acid levels > 4mg/dl have been associated
with complications of atherogenesis and stroke in individuals who are diabetic or at risk for
CVD (Lehto et al., 1998; Hayden and Tyagi, 2004). Serum uric acid in this cohort also run
high with more than 25 % and 76 % of individuals having serum uric acid levels more than 6
and 4mg/dl, respectively. These findings are a public health concern in a cohort that is at a
higher risk for CVD. Given the high rates of CVD and serum uric acid levels, investigation of
genetic factors that influence the variation in serum uric acid in this population is of utmost
importance. Therefore the primary aim of this study was to identify quantitative trait loci
(QTLs) influencing the variation in serum uric acid levels in American Indians.
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The SHFS is family-based genetic study in the American-Indian community. It is an extension
of the Strong Heart Study which is a population-based observational study of CVD and its risk
factors in this population. More than 3600 members of multigenerational families were enrolled
from all three centers located in Arizona, North and South Dakota and Oklahoma. The North
and South Dakota centers have been grouped together as one center as the SHFS participants
in the Dakotas are members of Sioux tribes whose reservations exist in both North and South
Dakota. The Indian Health Service Institutional Review Board and the institutional review
boards from the participating centers approved the SHFS protocol. All subjects gave informed
consent. Study design and methods of the SHFS have been described before (North et al.
2003).
Phenotyping
During a clinical visit, information related to anthropometry, alcohol intake, medical history
and medication use was obtained using a questionnaire. Weight was measured to the nearest
0.1 kilogram, using an ISO-9001 certified Scale-Tronix electronic scale with a capacity of 880
pounds (400 kilograms) (White Plains, NY). Standing height was measured twice, to the nearest
centimeter, using a SECA wall-mounted stadiometer (Seca Corp., Hanover, MD). Body mass
index (BMI) was computed as the ratio between weight in kilograms and height (in meters)
squared. Blood was collected after an overnight fast and plasma and serum samples were stored
at −80°C until analyzed. Fasting serum uric acid was oxidized in the presence of uricase to
form hydrogen peroxide, which was measured photometrically (Domagk et al. 1968). Serum
creatinine was estimated by modified kinetic Jaffe reaction (Beckman Synchron LX System,
Beckman Coulter, Fullerton, CA). Estimated glomerular filtration rate (eGFR) was computed
using the simplified modified diet and renal disease (MDRD) equation:
[eGFR (ml/min/1.73m2) = 186 × sCr (mg/dl)−1.154 × age (years)−0.203 × (1.212 if black)
× (0.742 if female)] (Levey et al. 1999; Myers et al. 2006).
Genotyping
Genotyping was conducted with DNA isolated from fasting blood samples using organic
solvents. All study participants were genotyped for about 400 microsatellite markers, using the
ABI PRISM Linkage Mapping Set-MD10 Version 2.5 (Applied Biosystems, Foster City, CA)
with markers spaced at an average interval of 10cM across the autosomal chromosomes.
Genotyping procedures have been described previously (North et al. 2006). Pedigree and
Mendelian errors were detected and corrected utilizing the software PREST (pedigree
relationship statistical tests) (Sun et al. 2002) and SIMWALK2 (Sobel et al. 1996),
respectively. Multipoint identity-by-descent (IBD) matrices for genome-wide linkage analyses
were calculated using the linkage analysis package (LOKI) (Heath 1997). The chromosomal
map used in these computations was based on marker locations reported by DeCode genetics
(Kong et al. 2002).
Quantitative genetic analysis
To detect genetic influence on the variation in serum uric acid and localize quantitative trait
loci (QTL) that affect serum uric acid, we employed a multipoint linkage analysis based on the
variance components decomposition approach, implemented in the software program SOLAR
and described in detail elsewhere (Blangero and Almasy 1997; Almasy and Blangero 1998).
In short, it is an extension of the variance components approach in which variance due to a
specific QTL is added to the basic model. It is based on estimating the effect of a specific QTL
on the variation in phenotype, and can be modeled as a function of the IBD relationship at the
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marker locus between family members. Traditionally, a logarithm of the odds (LOD) score,
which is computed directly from the likelihood ratio tests, is reported in linkage analyses
(Almasy and Blangero 1998).
An inverse normalization was performed for all traits after removing outliers greater than four
standard deviation from the mean. To conduct multipoint linkage analysis in the combined
sample, we combined samples from individual centers and used the cumulative data for
analysis, incorporating center as a covariate in the final model in addition to other covariates.
The serum uric acid was adjusted for the effects of factors that are known to influence its
variation using regression methods. The covariates age, sex, age*sex, BMI, eGFR, type 2
diabetes status, alcohol intake and medications were included in the final model. Relative pairs
that were major contributors to this study were parent-offspring, siblings, grandparent-
grandchild, avuncular, half siblings, first, second and third cousins. Details of these pairs are
shown in Table 1.
Results
3604 individuals (men = 1443, women = 2161) participated in this study. Of these, 1215 were
from Arizona, 1186 from Dakotas and 1203 from Oklahoma. The distribution of age, BMI and
serum uric acid by sex and center is given in Table 2. The overall mean ± SD serum uric acid
for all individuals was 5.14 ± 1.5 mg/dl. According to the criteria for increased serum uric acid
levels (men > 7 mg/dl and women > 6mg/dl) 12 %, 21 % and 17 % of individuals from Arizona,
Dakotas and Oklahoma, respectively had hyperuricemia. As has been observed in previous
studies (Mikkelsen et al. 1965;Freedman et al. 1995;Conen et al. 2004), men had higher levels
of serum uric acid than women in all centers, despite being younger and having lower BMI.
Approximately 20 % and 23 % of individuals had hypertension and type 2 diabetes,
respectively. With respect to medication usage, 13 % of the individuals were taking aspirin
and 15 % were taking angiotensin-converting enzyme (ACE) inhibitors. Approximately 7 %
were taking diuretics. Diabetic drugs, insulin, metformin and sulfonyureas were taken by 6 %,
8 %, and 10 % of the participants, respectively. Each medication group was tested separately
for significant effects on serum uric acid levels. The medication groups included aspirin, statins,
fibrates, insulin, sulfonylureas, metformins, thiazolidinediones, ACE inhibitors, ARBs, beta
blockers, calcium channel blockers, hydrocholrophiazides (diuretics), hypotensive agents,
alpha blocking agents and vasodilating agents. Of these, aspirin, sulfonylureas, metformin,
beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers and
hydrochlorothiazide (diuretics) were found to be significantly associated with serum uric acid.
The main effects of all covariates included in the final model are given in Table 3. Individuals
who were taking diabetic medications, metformin or sulfonylureas had lower serum uric acid
levels as compared to those who did not. However, individuals on aspirin or other blood
pressure lowering medications had higher serum uric acid levels than others (Table 4).
Univariate genetic analysis showed serum uric acid to be significantly heritable, with the
heritability being 0.46 ± 0.03 (p = 6.5 × 10−63) in all centers and 0.39 ± 0.07 (p = 4.6 ×
10−12), 0.51 ± 0.05 (p = 2.2 × 10−32), and 0.44 ± 0.06 (p = 1.5 × 10−18) in Arizona, Dakotas
and Oklahoma, respectively. Multipoint linkage analysis for serum uric acid conducted with
age, sex and their higher order terms and interactions as covariates showed evidence of linkage
on chromosome 11 with LOD scores of 3.0 and 2.1 in the combined data from all centers and
in the Dakota data, respectively (data not shown). Inclusion of additional, significant
covariates, BMI, eGFR, type 2 diabetes, alcohol intake and medications in the final model
improved the signal both in the Dakotas and in data from all centers, combined (Figure 1).
Linkage signals for Dakotas (LOD score = 3.02) and all centers (LOD score = 3.56) on
chromosome 11 at 71cM are shown in Figure 2. Both these QTLs had one LOD support
intervals of 22cM (Table 5). An additional QTL for serum uric acid was obtained for all centers
Voruganti et al. Page 4













on chromosome 1, with a significant LOD score of 3.51 (Figure 3). For Arizona, the highest
LOD score of 1.5 was obtained on chromosome 6 and for Oklahoma, a QTL on chromosome
8 was identified with a LOD score of 1.7.
Discussion
This is the first genome-wide study of variation in serum uric acid performed in American
Indians. We found significant genetic influence on the variation in serum uric acid levels and
identified two novel QTLs on chromosomes 1 and 11. Increased serum uric acid is a risk factor
for gout, renal disease and CVD and is known to aggregate in families (Stecher et al. 1949;
Dixon 1960; Friedlander et al. 1988; Cameron and Simmonds 2005; Nakagawa et al. 2006).
We found significant heritability for serum uric acid in all centers confirming a genetic
influence on its variation. Furthermore, heritabilities obtained in this study are in the same
range as those reported by previous family-based genetic studies of individuals of different
ancestry (Rao et al. 1982; Tang et al. 2003; Yang et al. 2005; Nath et al. 2007; Voruganti et
al. 2009).
It is likely that multiple genes, and not a single gene influence the variation in serum uric acid
(Wilk et al. 2000). Multiple QTLs have been reported in genome-wide scans of serum uric
acid with little overlap in populations. This may be due to confounding by population
stratification, or possibly due to genetic heterogeneity of this common, complex trait. Yang et
al. (2005) reported a QTL on chromosome 15q (LOD = 3.3) for serum uric acid in a Caucasian
population from the Framingham Heart Study. In another study, using serum uric acid as a part
of the metabolic syndrome, a QTL was localized on chromosome 2q (Tang et al. 2003). Among
Mexican Americans, a strong QTL for serum uric acid levels was found on chromosome 6 and
a suggestive linkage on chromosome 3 (Nath et al. 2007). In a subsequent follow up study with
a larger sample of individuals, the linkage on chromosome 3 reached genome-wide significance
with a LOD score of 4.7 (Voruganti et al. 2009). Our study identified new QTLs for serum
uric acid relevant to our population of American Indians.
Genome-wide association studies (GWAS) for gene discovery have been conducted mostly in
individuals of European ancestry. These studies are biased towards common variants and the
gene coverage varies depending on the platform used for genotyping. However, findings from
GWAS have been more consistent. They identified common variants in solute carrier family2,
member 9 (SLC2A9) that were associated with serum uric acid (Li et al. 2007; Vitart et al.
2008; Doring et al. 2008; Brandstattter et al. 2008; Stark et al. 2008; Wallace et al. 2008;
Dehghan et al. 2008b; Matsuo et al., 2008). Interestingly, SLC2A9 encodes a transporter for
urate as well as fructose, and is known to influence serum uric acid levels (Vitart et al. 2008).
Within the confidence interval of our QTL for serum uric acid on chromosome 11 lies the gene
for URAT1, solute carrier family22, member 12 (SLC22A12). URAT1 is an urate-anion
exchanger and the main transporter responsible for reabsorption of uric acid from the
glomerular filtrate in the apical membrane of the renal tubules (Enomoto et al. 2002). Mutations
in SLC22A12 have been associated with hypouricemia in Japanese patients (Enomoto et al.
2002; Komoda et al. 2004; Takahashi et al., 2005; Wakida et al., 2005; Ichida et al. 2008; Lee
et al., 2008) and Korean men (Jang et al. 2008).
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=220150.
A strong linkage signal for serum uric acid was localized to chromosome 1p36. Prominent
candidate genes in this region are the kidney chloride channel A and B (CLCNKA and
CLCNKB) genes. The CLCNKA and CLCNKB channels are part of a family of mammalian
chloride channels (Saito-Ohara et al. 1996). Mutations in these genes cause Bartter’s syndrome
type 3 which is characterized by impaired salt reabsorption, salt wasting, hypokalemic
metabolic alkalosis and hypercalciuria (Simon et al. 1997). Metabolic alkalosis can decrease
Voruganti et al. Page 5













the excretion of uric acid thus contributing to hyperuricemia in patients with this type of
Bartter’s syndrome (Meyer et al. 1975). Thus these genes are strong positional candidate genes
that may influence variation in serum uric acid in American Indians.
The rate of urate excretion and its renal handling play a major part in the variation of serum
uric acid levels (Sica and Schoolwerth 2002). Therefore, medications that affect renal urate
excretion have a significant influence on serum uric acid levels. Drugs such as losartan, have
been shown to reduce serum uric acid levels by reducing its reabsorption from kidneys (Sica
and Schoolwerth 2002). In the current study, among the medications that were associated with
and adjusted against serum uric acid [aspirin, sulfonylureas, metformin, ACE inhibitors, beta
blockers, calcium channel blockers and diuretics], diuretics was the most significant group.
Diuretics, usually prescribed as the primary treatment for hypertension, are known to increase
serum uric acid by increasing its reabsorption. They had the maximum effect on serum uric
acid levels in all centers, except Arizona, when compared to other medications. Similarly beta
blockers and ARBs, with the exception of losartan, are believed to increase serum levels of
uric acid (Reyes 2003). Earlier genetic analyses explored diuretics and aspirin for effects on
variation in serum uric acid (Wilk et al. 2000; Yang et al. 2005). However, the current study
is the first one to investigate not only the effects of cardiovascular drugs such as ARBs, ACE
inhibitors, beta blockers, calcium channel blockers and diuretics but also diabetic drugs such
as sulfonylureas, metformin and insulin on the variation in serum uric acid levels. We observed
that individuals taking metformin or sulfonyureas have comparatively lower levels of serum
uric acid than those who don’t take these medications. Serum uric acid has been linked to
insulin resistance (Clausen et al., 1998; Yoo et al., 2005) and has often been advocated to be
a part of the metabolic syndrome (Nakagawa et al., 2005; Cirillo et al., 2006). It has been
reported that drugs such as metformin that improve insulin sensitivity are also known to
decrease serum uric acid levels (Tsouli et al., 2006). On the other hand, we observed that blood
pressure lowering medications have an adverse effect on serum uric acid levels. Diuretics
increase serum uric acid levels by either affecting its secretion or increased distal reabsorption
(Langford et al., 1987). ACE inhibitors are known to have a mild reducing effect on serum
uric acid levels helping blunt the effect of diuretics (Reyes, 2003) however this was not
observed in individuals in our study. Even though drugs that lower serum uric acid have not
shown substantial improvements in vascular mortality, increased serum uric acid values
provide useful prognostic information in individuals at risk for CVD (Wannamethee 2005).
In summary, we identified two new loci on chromosomes 11q and 1q for variation in serum
uric acid among American Indians, where strong positional candidate genes are located. Given
the importance of serum uric acid as a likely biomarker and a potential independent risk factor
for CVD, and the recent increase in CVD mortality in American Indians, these results assume
considerable significance.
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Univariate linkage analysis by each chromosome (all centers and individual centers).
Chromosomal location (cM) is represented on the x-axis and the LOD score shown on the y-
axis. All – grey; Dakotas – blue; Oklahoma – green; Arizona - red
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Evidence of significant linkage for serum uric acid on chromosome 11 in Dakotas and all
centers. Chromosomal location (cM) is represented on the x-axis and LOD score is shown on
the y-axis. All – Solid line; Dakotas – dashed line
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Evidence of significant linkage for serum uric acid on chromosome 1 in all centers.
Chromosomal location (cM) is represented on the x-axis and LOD score is shown on the y-
axis
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Table 1
Relative pairs utilized in this study
Relationship ALL AZ DK OK
Parent-offspring 2822 842 1026 954
Siblings 2657 846 941 870
Grandparent-grandchild 1068 361 375 332
Avuncular 6741 1961 2555 2225
Half siblings 943 304 323 316
Grand avuncular 3027 782 1236 1009
Half avuncular 1393 441 422 530
First cousins 9148 2801 3517 2830
First cousins, once removed 12562 3676 5027 3859
Half first cousins 1325 523 375 427
First cousins, twice removed 1485 354 389 742
Half first cousins, once removed 1607 799 266 542
Second cousins 7083 2184 3060 1839
Second cousins, once removed 2697 869 967 861
Half second cousins 801 421 133 247
Third cousins 915 180 562 173
Others 3075 689 1312 1074
Total 59349 18033 22486 18830
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Table 5





Flanking markers One LOD
support interval
ALL 3.51 1 (39cM) D1S199 and D1S234 31–43cM
3.56 11 (71cM) D11S4191 and D11S987 55–77cM
AZ 1.5  6 (68cM) D6S1610 and D6S257 60–81cM
DK 3.02 11 (71cM) D11S4191 and D11S987 55–77cM
OK 1.7  8 (40cM) D8S258 and D8S1771 35–44cM
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